In­ven­ti­va stock sinks 20% af­ter se­ri­ous ad­verse event in NASH tri­al leads to en­roll­ment pause

In­ven­ti­va has paused screen­ing and en­ter­ing new pa­tients in its Phase III NASH study for lan­i­fi­bra­nor af­ter a pos­si­bly treat­ment-re­lat­ed ad­verse event.

The com­pa­ny said a pa­tient ex­pe­ri­enced se­ri­ous el­e­vat­ed amino­trans­feras­es, a type of liv­er en­zymes. While screen­ing and ran­dom­iza­tion of pa­tients have tem­porar­i­ly come to a stop, those al­ready en­rolled in the tri­al are con­tin­u­ing treat­ment. In­ven­ti­va said this is the first treat­ment-re­lat­ed Sus­pect­ed Un­ex­pect­ed Se­ri­ous Ad­verse Re­ac­tion, or SUSAR, in all clin­i­cal tri­als in­ves­ti­gat­ing lan­i­fi­bra­nor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER